Doomed Dendreon? Some Speculators Shocked By Sales Again Print E-mail
By Brian Wilson, Contributor   
Thursday, 02 August 2012 00:00
icon_newsnotesDendreon (DNDN) has been a disastrous holding for many investors who may have been initially optimistic about the company’s drug PROVENGE. I initiated coverage on the distressed biotech name on July 21st of this year with a hold rating. I certainly did not want my followers to buy any more of the stock, and I had my reservations about a cold-blooded sell recommendation due to the extreme bearishness surrounding the company.
Read more...
 
Former Chairman and CEO of Celgene Believes His New Firm Can Become "A Substantial Player" in Biotech Print E-mail
By M.E.Garza   
Wednesday, 01 August 2012 02:06
icon_qaexclusiveNo doubt, one of the biggest biotech surprises out of the starting gate this year has been Medgenics Inc. (AMEX:MDGN). The stock ran big shortly after their introduction to the market as shares traded from $2.08 to $16.43 in short order-- an impressive run fueled in part by the company's extremely low float and excited reaction by investors.
Read more...
 
Pluristem's New Indication for Pulmonary and Lung disorders Expands Blockbuster Pipeline Print E-mail
By Ray Dirks of Ray Dirks Research   
Tuesday, 31 July 2012 07:23
icon_closerlookThis morning, Pluristem Therapeutics (NASDAQ:PSTI) is once again making news. This time with a new way to treat Pulmonary fibrosis; where a person's lungs become so scarred that breathing is impossible. It strikes 5 million people per year around the world, and 200,000 in the US. Most die because there is no cure.
Read more...
 
Updated: Roth Capital’s Says Amarin's Approval Provides Visibility for Neptune reiterates Buy rating and $10.30 price target Print E-mail
By M.E.Garza   
Friday, 27 July 2012 07:42
icon_tradedispatchIn a flash note to clients on Friday, Roth Capital Partners’ analyst Joseph Pantginis, Ph.D.,says that Thursday’s FDA approval for Amarin Corporation’s (NASDAQ:AMRN) Vascepa bodes well for Neptune Technologies & Bioressources’ (Nasdaq:NEPT) (TSX:NTB) underlying and growing core NKO business as well as the pharmaceutical opportunity with Acasti's CaPre.
Read more...
 
Closer Look: Repros Therapeutics Print E-mail
By Brian Wilson, Contributor   
Friday, 27 July 2012 06:15
icon_closerlookRepros Therapeutics Inc. (NASDAQ:RPRX) caught the attention of biotech investors after its ~120% rally in May, which sent the stock from a market cap of approximately $63 million to its current $140 million. Biotech investors looking at this firm’s history can quickly note that the IPO for RPRX was initiated all the way back in 1993.
Read more...
 
Short Squeeze & Speculation Could Push Onyx and Ligand Higher Print E-mail
By Brian Wilson, Contributor   
Thursday, 26 July 2012 07:20
icon_tradethesisWhen I last covered Onyx Pharmaceuticals (NASDAQ:ONXX) on June 19th, the company was trading at a market capitalization of approximately $3 billion dollars ahead of a review of Kyprolis (carfilzomib) by the FDA’s Oncologic Drugs Advisory Committee (ODAC).
Read more...
 
Sagent Pharmaceuticals CEO Sees Big Market Opportunity For His Firm Print E-mail
By Staff and Wire Reports   
Tuesday, 24 July 2012 12:50
In an exclusive video interview with healthcare analyst Avik Roy, Sagent Pharmaceuticals' (NASDAQ:SGNT) President and CEO Jeff Yordon says his specialty pharmaceutical company that develops, manufactures, sources and markets pharmaceutical products is drafting unique contracts with its customers.
Read more...
 
Dendreon’s PROVENGE Needs To Pull Itself Together Soon Print E-mail
By Brian Wilson, Contributor   
Tuesday, 24 July 2012 04:58
icon_newsnotesDendreon (DNDN), a big name in the prostate cancer world, is struggling to heavily market the drug PROVENGE ® much to the dismay of its shareholders. DNDN was trading around $38/share a year ago, but have fallen more than 80% as a double-whammy of underwhelming sales data and very narrow profit margins brought the company into negative-EPS territory.
Read more...
 
Placenta Based Stem Cells: The Investment of the Future is Now Print E-mail
By Scott Matusow, Contributor   
Monday, 23 July 2012 06:26
icon_stockresearchTrying to find companies that represent the future of the biotech sector can be tricky for investors. The sector currently leads the market because Food and Drug Administration (FDA) regulatory guidance is changing, with restrictions easing, and new guidelines being proposed and implemented.
Read more...
 
Can Array BioPharma's Bullish Breakout Continue? Print E-mail
By M.E.Garza   
Monday, 23 July 2012 01:52
icon_marketmoverShares of Array BioPharma (NASDAQ:ARRY) have soared since we first told readers that the firm was planning to partner more products.
Read more...
 
<< Start < Prev 51 52 53 54 55 56 Next > End >>

Page 54 of 56

Newsletter